 |
|
A Randomized, Double-blind, Vehicle-Controlled Study to Assess 5% Imiquimod Cream for the Treatment of Multiple Actinic Keratoses
Eggert Stockfleth, MD;
Thomas Meyer, PhD;
Bernd Benninghoff, PhD;
Stuart Salasche, MD;
Latza Papadopoulos;
Claas Ulrich, MD;
Enno Christophers, MD
Arch Dermatol. 2002;138:1498-1502.
Background Actinic keratoses (AKs) are precancerous epidermal lesions found most frequently on areas of the skin exposed to the sun. Several case studies published recently have indicated that 5% imiquimod cream, currently licensed for the treatment of genital warts, may be an effective treatment for AK.
Objective To assess the efficacy and safety of imiquimod for the treatment of AK.
Design Patients in this randomized, double-blind, vehicle-controlled study applied 5% imiquimod cream or vehicle to AK lesions 3 times per week for a maximum of 12 weeks or until lesions had resolved. In the event of an adverse reaction, application of imiquimod was reduced to 1 or 2 times per week. Rest periods were also allowed if necessary.
Setting A specialized outpatient dermatology clinic within a state-funded hospital in Germany.
Patients The study population was aged 45 to 85 years. Of 52 patients screened, 36 men and women with AK confirmed by histological diagnosis were enrolled. Patients were excluded from the study if they did not have a histological diagnosis for AK, if they were older than 85 years, or if they did not comply with the protocol. All patients had responded to a notice asking for volunteers.
Main Outcome Measures The number and appearance of lesions were evaluated before, during, and after treatment. All adverse effects were recorded.
Results Lesions treated with 5% imiquimod cream were clinically cleared in 21 (84%) of 25 patients and partially cleared in 2 (8%). Clearance was histologically confirmed 2 weeks after the last application of imiquimod in all patients clinically diagnosed as lesion free. Only 10% of patients treated with imiquimod were clinically diagnosed with recurrence 1 year after treatment. No reduction in the size or number of AK lesions was observed in vehicle-treated patients. Adverse effects reported by patients treated with imiquimod included erythema, edema, induration, vesicles, erosion, ulceration, excoriation, and scabbing. However, imiquimod was well tolerated since all patients completed the 12-week treatment. Only a few, mild adverse reactions to the vehicle cream were reported.
Conclusion Application of 5% imiquimod cream for 12 weeks is an effective and well-tolerated treatment for AK.
From the Department of Dermatology, University of Kiel, Kiel (Drs Stockfleth, Ulrich, and Christophers, and Mr Papadopoulos), Institute of Immunology, Pathology and Molecular Biology (IPM), Hamburg (Dr Meyer), and 3M Medica, Borken (Dr Benninghoff), Germany; and Dermatology Division, University of Arizona Health Sciences Center, Tuscon (Dr Salasche). Drs Stockfleth and Ulric are now with the Department of Dermatology, Humboldt University, Berlin, Germany.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Smits et al.
The Oncologist 2008;13:859-875.
ABSTRACT
| FULL TEXT
Safety and Efficacy of 5% Imiquimod Cream for the Treatment of Skin Dysplasia in High-Risk Renal Transplant Recipients: Randomized, Double-blind, Placebo-Controlled Trial
Brown et al.
Arch Dermatol 2005;141:985-993.
ABSTRACT
| FULL TEXT
Amelioration of Acute Renal Failure by Stem Cell Therapy--Paracrine Secretion Versus Transdifferentiation into Resident Cells: Administered Mesenchymal Stem Cells Protect against Ischemic Acute Renal Failure through Differentiation-Independent Mechanisms. Am J Physiol Renal Physiol E-pub February 15, 2005
Togel et al.
J. Am. Soc. Nephrol. 2005;16:1153-1163.
FULL TEXT
Topically applied imiquimod 5% cream cleared actinic keratosis lesions
Sinclair
Evid. Based Med. 2005;10:11-11.
FULL TEXT
Low Incidence of New Actinic Keratoses After Topical 5% Imiquimod Cream Treatment: A Long-term Follow-up Study
Stockfleth et al.
Arch Dermatol 2004;140:1542-1542.
FULL TEXT
Treatment of Photoaging
Stern
NEJM 2004;350:1526-1534.
FULL TEXT
A Trial of Short Incubation, Broad-Area Photodynamic Therapy for Facial Actinic Keratoses and Diffuse Photodamage
Touma et al.
Arch Dermatol 2004;140:33-40.
ABSTRACT
| FULL TEXT
Imiquimod: A Topically Applied Link Between Innate and Acquired Immunity
Hurwitz et al.
Arch Dermatol 2003;139:1347-1350.
FULL TEXT
Fill the Mind--and Exercise It, Too!
Ackerman
Arch Dermatol 2003;139:940-940.
FULL TEXT
Imiquimod for Actinic Keratoses
Journal Watch Dermatology 2002;2002:1-1.
FULL TEXT
|
